Last reviewed · How we verify
MIBG
At a glance
| Generic name | MIBG |
|---|---|
| Also known as | <131>I-Metaiodobenzylguanidine |
| Sponsor | Nationwide Children's Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (PHASE1,PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma (PHASE2)
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma (PHASE2)
- Next Generation Personalized Neuroblastoma Therapy (PHASE1)
- Terazosin and Parkinson's Disease Extension Study (PHASE2)
- Cardiac Changes in Early Parkinson's Disease: A Follow up Study (PHASE2)
- Terazosin Effect on Cardiac Changes in Early Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MIBG CI brief — competitive landscape report
- MIBG updates RSS · CI watch RSS
- Nationwide Children's Hospital portfolio CI